Read the latest news about Healx and our goal to advance treatments for rare diseases.
We are pleased to announce the appointment of Neil Thompson, PhD, as Chief Scientific Officer (CSO). Neil will spearhead the expansion of the drug discovery and development team at Healx, as the company continues its growth as a leading AI-powered, next-generation biopharmaceutical company. Healx is pioneering in that it takes a patient-first approach and integrates … Continued
Healx (healx.io), today announced a partnership with Boston Children’s Hospital and Barth Syndrome Foundation (BSF) to advance promising therapeutic compounds using a novel approach that will accelerate drug discovery for applications in Barth syndrome
Kate has extensive expertise in drug discovery and her appointment underlines our mission to combine deep pharmacological expertise with Artificial Intelligence
We are delighted to announce $10 million Series A funding round, led by Balderton Capital. Existing investors, Jonathan Milner and Amadeus Capital Partners also participated in the round.
The Business Weekly article also covers the appointment of Shaun Grady, a leading business development executive at Astra Zeneca, to Healx’s board of directors